Tumor mutation burden

1. Low aging scores decrease tumor mutation burden in silico.

   “patients with low aging scores (LAS group) exhibited better survival, lower tumor mutation burden (TMB)”

   In silicocomparing LAS group to HAS group

   Exploring the molecular and immune landscape of cellular senescence in lung adenocarcinoma

   Frontiers in immunology·Aug 29, 2024

More on Low aging scores

1. Age increases tumor mutation burden in humans (0.077 mutations per megabase per year).

   “Age influences both the number of mutations in a tumour (0.077 mutations per megabase per year) and their evolutionary timing.”

   Humans

   Age influences on the molecular presentation of tumours

   Nature communications·Jan 11, 2022

1. Senescence-risk signature is associated with tumor mutation burden in silico.

   “the risk score was positively associated with tumor mutation burden (TMB) and immune checkpoint”

   In silicoprostate cancer patients

   Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer

   Frontiers in immunology·Feb 20, 2023

More on Senescence-risk signature

1. mitosis breast cancer subtype is associated with tumor mutation burden in humans (highest).

   “the mitosis subtype had the highest tumor mutation burden”

   Humansbreast cancerbreast cancer

   Epigenetic clock detected a breast cancer mitosis subtype with improved immunotherapy

   Research Square·Feb 18, 2021Preprint